See a Demo

Transparent Thinking Blog

TrialAssure cubes divider
The following case study is based on real work conducted between TrialAssure, MMS, and a top 10 pharma sponsor to accelerate the development of Clinical Study Reports using TrialAssure LINK AI. Problem A top 10 global pharma company launched a challenge to evaluate AI-augmented medical writing for Draft 1 Clinical Study Reports (CSRs). The AI system was required to operate fully within the sponsor’s secure cloud environment and integrate with its proprietary Large Language Model (LLM) under strict governance requirements. The timeline was compressed. After receiving protocols, SAPs, and an extensive list of TLFs, the team had a narrow window to generate both a Draft 1 CSR and Plain Language Summary (PLS). The challenge demanded an unprecedented level of speed and technical precision, with just three (3) days to set up the technical environment and five (5) days to complete the actual document drafts. Solution Using its AI-assisted authoring platform, LINK AI, TrialAssure was selected as one of just a few providers to participate in this program, partnering with MMS, a data-focused CRO, to rapidly deploy the solution within the sponsor’s cloud environment. The team seamlessly integrated the platform with the sponsor’s approved LLMs, configured a structured, AI-driven workflow, and securely ingested sponsor-provided source documents within an accelerated implementation timeline. Our medical writers accessed the sponsor environment to review outputs, refine prompts in real time, and strengthen complex results sections. The team integrated PLS development into the same workflow and produced English, French, and German versions. Then, our technical team addressed deployment and model integration challenges quickly, combining AI acceleration with experienced human oversight. “The team brought strong technical knowledge and medical writing experience together in a way that felt seamless. We were impressed by how responsive the team was, and the improvements made over a short period gave us confidence in its long-term potential.” Results The team successfully delivered a full Draft 1 CSR and PLSs in three (3) languages within just 24 hours of receiving source documents. Additionally, we were able to: Strengthen and expand the CSR template and prompt library. Provide rapid output improvements within mere days. Prove the successful deployment inside a controlled enterprise environment. Position a clear pathway for future enterprise AI-assisted medical writing initiatives. This challenge demonstrated that AI-augmented medical writing with TrialAssure’s LINK AI can function effectively within the strict infrastructure of any pharmaceutical and biotech organization.

Accelerating AI-Augmented CSR Development for a Top Global Biopharma Sponsor

by Staff Writer | April 2026

Posted in Blog, Case Studies
Read More
AI for Medical Writing Certification (AIMWC) Program

AI in Medical Writing Certification Program Launched by TrialAssure to Support Greater Adoption Across Pharma and Biotech

by Staff Writer | March 2026

Posted in Blog, News
Read More
Austin TX

TrialAssure to Lead Discussions on CCI and Smart Anonymization at PHUSE US Connect 2026 in Austin

by Staff Writer | February 2026

Posted in Blog, News
Read More
How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

by Staff Writer | January 2026

Posted in Blog, Case Studies
Read More
TrialAssure Establishes Physical Presence in The Netherlands

TrialAssure Establishes Physical Presence in The Netherlands to Advance Clinical Trial Transparency and Data Sharing Across Europe

by Staff Writer | January 2026

Posted in Blog, News
Read More
Typing on keyboard

Experts Share Real-World Lessons to Applying AI in Medical Writing

by Staff Writer | December 2025

Posted in Blog
Read More
TrialAssure Officially Granted New Patent for Date Offset Anonymization Technology by U.S. Patent and Trademark Office

TrialAssure Officially Granted New Patent for Date Offset Anonymization Technology by U.S. Patent and Trademark Office

by Staff Writer | December 2025

Posted in Blog, News
Read More
Chris Hurley

Respected Data Science Industry Leader Chris Hurley Joins TrialAssure Advisory Leadership Team to Strengthen Data Strategy and Innovation

by Staff Writer | December 2025

Posted in Blog, News
Read More
How TrialAssure is Building Better DSURs with Purpose-Built Prompts, Smarter Sources, and a Proven Approach | pharma, biotech, life sciences, medical device

How TrialAssure is Building Better DSURs with Purpose-Built Prompts, Smarter Sources, and a Proven Approach 

by Zach Weingarden | November 2025

Posted in Blog
Read More
TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech Innovative application architecture gives users clearer insight into AI responses, improves output reliability, and strengthens data alignment across LINK AI®, ANONYMIZE®, and REGISTRY® CANTON, Mich. (October 7, 2025) – TrialAssure, a leading technology provider advancing clinical trial transparency, disclosure, and data sharing, announced the launch of its new enhanced content search and sourcing capability, a technical upgrade designed to boost accuracy, transparency, and reliability across its suite of AI-powered tools. This advancement enables a more structured way for artificial intelligence (AI) to interpret, segment, and retrieve information from source documents, enabling users to gain more precise insights and greater control over the content. TrialAssure has introduced an integrated framework that leverages AI Large Language Models (LLMs) to process and manage content more effectively. This framework emphasizes efficient document ingestion and chunking, optimized embedding and indexing, structured information storage, and advanced AI prompt design and engineering. These techniques replace the out-of-the-box indexing and retrieval approaches and improve the visibility and traceability of AI responses, giving users greater confidence and a more efficient approach to generating structured and regulated documents in the life sciences arena. This also creates a more flexible and tailored experience, allowing AI models to separate, label, and group source material with greater specificity. For instance, information used to create clinical narratives can now be isolated by individual trial participants to eliminate cross-contamination and improve document fidelity. “Giving the pharma and biotech industry clarity into how AI reaches its outputs was a technical challenge at first, but it is our usability promise,” said Zach Weingarden, MS, Director of AI Technology & Applications, TrialAssure. “We are focused on raising the standard for how AI can operate transparently in highly regulated environments like life sciences.”

TrialAssure Introduces Enhanced Architectural Techniques to Improve Accuracy, Visibility, Traceability, and Control Across its AI Platform for Pharma and Biotech

by Staff Writer | October 2025

Posted in Blog, News
Read More
Get in Touch

Looking to streamline your clinical trial disclosure and transparency efforts?

TrialAssure is ready to help your organization embark on a Transparency Transformation!

To learn more about the TrialAssure Transparency Suite, specific products, or our company, contact us below.

Yes, please send me more information about TrialAssure.